大流行
病毒学
2019年冠状病毒病(COVID-19)
冠状病毒
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药物开发
RNA依赖性RNA聚合酶
药物发现
2019-20冠状病毒爆发
病毒
RNA聚合酶
计算生物学
生物
核糖核酸
聚合酶
药品
医学
生物信息学
药理学
遗传学
DNA
传染病(医学专业)
基因
疾病
病理
爆发
作者
Narva Deshwar Kushwaha,Jivanka Mohan,Babita Kushwaha,Terisha Ghazi,Joshua C. Nwabuife,Neil A. Koorbanally,Anil A. Chuturgoon
标识
DOI:10.1016/j.ejmech.2023.115719
摘要
The recently discovered coronavirus, known as SARS-CoV-2, is a highly contagious and potentially lethal viral infection that was declared a pandemic by the World Health Organization on March 11, 2020. Since the beginning of the pandemic, an unprecedented number of COVID-19 vaccine candidates have been investigated for their potential to manage the pandemic. Herein, we reviewed vaccine development and the associated research effort, both traditional and forward-looking, to demonstrate the advantages and disadvantages of their technology, in addition to their efficacy limitations against mutant SARS-CoV-2. Moreover, we report repurposed drug discovery, which mainly focuses on virus-based and host-based targets, as well as their inhibitors. SARS-CoV-2 targets include the main protease (Mpro), and RNA-dependent RNA-polymerase (RdRp), which are the most well-studied and conserved across coronaviruses, enabling the development of broad-spectrum inhibitors of these enzymes.
科研通智能强力驱动
Strongly Powered by AbleSci AI